Finance
Avantogen details $5.7 million fully underwritten non-renounceable rights issue
Published in Vaccine Weekly, April 26th, 2006
Eligible Avantogen shareholders will be offered one new share for every four shares they hold, as at April 6, 2006, at an issue price of AUD0.105 cents per share. Shareholders will also receive 1 option for every 2 rights they take up. The option will be listed, have an exercise price of AUD0.25 cents and will expire on December 31, 2007. The rights issue has been fully underwritten by BBY Limited.
Avantogen CEO, Dr. Leonard Firestone, said, "The funds will be used to consummate our recently announced...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-04-26)
More Articles from Vaccine Weekly
- Anthrax Vaccine
N-fragment of edema factor is candidate antigen for anthrax vaccine - Avian Influenza Vaccine
Adenovirus-based vaccine protects against lethal H5N1 avian influenza - Helicobacter Vaccine
CTA1-DD adjuvant enhances immunity against Helicobacter pylori infection - Rotavirus Vaccine
Rectally delivered vaccine protects mice against rotavirus infection - SARS Vaccine
Inactivated Vero-cell SARS vaccine is safe and effective in monkeys - Allergy & Immunology
Recombinant allergens, hypoallergenic derivatives are potential type I allergy therapy - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
